|Bid||29.78 x 100|
|Ask||29.80 x 100|
|Day's Range||29.73 - 30.13|
|52 Week Range||24.45 - 53.16|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Ironwood Pharmaceuticals told shareholders Monday that it's learned biotech activist investor Alex Denner of Sarissa Capital is seeking to join its board.
The Medicines Company (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
But what is clear is that in the not too distant future, PCSK9 inhibitors will be priced in a way that will be palatable to payers thereby making this class of important drugs available to those whose lives can be saved or prolonged by them.
Esperion popped Monday after a study from Regeneron and Sanofi validated the long-term benefits of lowering LDL cholesterol.
Alnylam Pharmaceuticals (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medicines Company said in a regulatory filing it was restructuring its board by reducing the number of members to 7 from 12. The company said it would nominate Denner, along with Fredric Eshelman, Geno Germano, John Kelly, Clive Meanwell, Paris Panayiotopoulos and Sarah J. Schlesinger to the board.
Medicines Company shares surged 6.2% in heavy morning trade on Thursday after the company reported plans to restructure its board and reduce the number of board members from 12 to seven in a financial ...
Medicines Company (MDCO) incurs wider-than-expected loss in the fourth quarter of 2017. Moreover, the top line declines year over year on low Angiomax sales.
The Parsippany, New Jersey-based company said it had a loss of $2.45 per share. Losses, adjusted to account for discontinued operations, came to $2.19 per share. The results missed Wall Street expectations. ...